DDFG Inc Has $717,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

DDFG Inc lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 27.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,752 shares of the medical research company’s stock after selling 1,023 shares during the quarter. DDFG Inc’s holdings in Amgen were worth $717,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in AMGN. Capital Performance Advisors LLP acquired a new stake in Amgen during the 3rd quarter worth $25,000. Centricity Wealth Management LLC acquired a new stake in Amgen during the 4th quarter worth $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen during the 3rd quarter worth $29,000. Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter worth $36,000. Finally, PrairieView Partners LLC increased its holdings in Amgen by 118.3% during the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock worth $46,000 after purchasing an additional 97 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.9 %

Amgen stock opened at $310.78 on Tuesday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock has a market capitalization of $166.95 billion, a P/E ratio of 41.16, a PEG ratio of 2.63 and a beta of 0.56. The stock has a 50-day simple moving average of $281.80 and a 200 day simple moving average of $299.73.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.06%. Amgen’s dividend payout ratio (DPR) is 126.09%.

Insiders Place Their Bets

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock worth $20,644,335 over the last three months. Insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on AMGN shares. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Deutsche Bank Aktiengesellschaft lowered their target price on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Piper Sandler Companies reiterated an “overweight” rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Finally, UBS Group reiterated a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus price target of $314.09.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.